Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., a Member Enterprise of Fosun Pharma, Submits Listing Application to HKEX

NewTimeSpace News: Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd. submitted its listing application to HKEX on 26 June 2026, with China International Capital Corporation (CICC) and Fosun International Capital Limited appointed as joint sponsors.

As a member enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., the Company has deep cultivation in China’s preventive vaccine industry for more than two decades. It is a fully integrated vaccine enterprise covering the entire industrial chain of vaccine R&D, manufacturing and commercialization, centering on innovative vaccines. It has established a solid industry foothold with technologies including recombinant protein vaccines, polysaccharide/conjugate vaccines, as well as attenuated and inactivated vaccines. The Group runs two R&D and production bases located in Chengdu and Dalian.

Its commercialized vaccine portfolio comprises Human Rabies Vaccine (Vero Cell), Lyophilized Human Rabies Vaccine (Vero Cell), Trivalent Split Influenza Virus Vaccine and Quadrivalent Split Influenza Virus Vaccine. For the full year 2025, the Company ranked third in China’s human rabies vaccine market with 7.351 million lot-release doses issued, while its trivalent split influenza vaccine took second place in the corresponding segment with 3.973 million lot-release doses. Throughout the Track Record Period, all its commercialized vaccines recorded a 100% pass rate in official lot-release quality audits.

In terms of product pipeline, the Company boasts nine candidate products covering six disease areas, including 13-valent pneumococcal conjugate vaccine (PCV13) in Phase III clinical trials, Lyophilized Human Rabies Vaccine (Human Diploid Cell) which has entered Phase III trials, and 24-valent pneumococcal conjugate vaccine (PCV24) under Phase I clinical evaluation.